Barnett & Company Inc. lowered its stake in Celgene Corporation (NASDAQ:CELG) by 4.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,080 shares of the biopharmaceutical company’s stock after selling 50 shares during the period. Barnett & Company Inc.’s holdings in Celgene Corporation were worth $134,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Motco increased its position in Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 620 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Celgene Corporation during the first quarter worth about $118,000. Carroll Financial Associates Inc. increased its position in Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 400 shares in the last quarter. Oakworth Capital Inc. increased its position in Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 412 shares in the last quarter. Finally, Reilly Financial Advisors LLC increased its position in Celgene Corporation by 15.3% in the first quarter. Reilly Financial Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 161 shares in the last quarter. Institutional investors and hedge funds own 78.39% of the company’s stock.
Shares of Celgene Corporation (NASDAQ CELG) opened at 136.70 on Friday. The firm has a market cap of $106.95 billion, a price-to-earnings ratio of 42.34 and a beta of 1.89. Celgene Corporation has a one year low of $96.93 and a one year high of $139.00. The company has a 50 day moving average of $132.00 and a 200-day moving average of $123.32.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.61 by $0.21. The business had revenue of $3.27 billion during the quarter, compared to the consensus estimate of $3.23 billion. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The firm’s revenue was up 18.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.44 EPS. On average, analysts expect that Celgene Corporation will post $7.32 EPS for the current year.
A number of analysts have weighed in on CELG shares. Leerink Swann raised Celgene Corporation from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $94.42 to $150.00 in a research report on Friday, June 16th. They noted that the move was a valuation call. Goldman Sachs Group, Inc. (The) reaffirmed a “sell” rating and set a $98.00 price objective (up from $93.00) on shares of Celgene Corporation in a research report on Wednesday, May 17th. William Blair reissued an “outperform” rating on shares of Celgene Corporation in a report on Monday, June 26th. BTIG Research cut Celgene Corporation from a “buy” rating to a “neutral” rating and raised their price target for the company from $96.93 to $131.70 in a report on Friday, June 30th. Finally, Canaccord Genuity set a $156.00 price target on Celgene Corporation and gave the company a “buy” rating in a report on Monday, May 22nd. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and twenty-three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $147.06.
In other Celgene Corporation news, insider Rupert Vessey sold 4,785 shares of the company’s stock in a transaction that occurred on Thursday, June 15th. The shares were sold at an average price of $120.18, for a total value of $575,061.30. Following the completion of the transaction, the insider now directly owns 4,004 shares in the company, valued at approximately $481,200.72. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Michael D. Casey sold 9,250 shares of the company’s stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $125.59, for a total transaction of $1,161,707.50. The disclosure for this sale can be found here. In the last three months, insiders sold 235,255 shares of company stock valued at $31,377,042. 0.95% of the stock is owned by insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
